NKTX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 19.15%, SMA50 25.24%, SMA200 29.83%). The stock’s 14-day RSI is 70.25 (overbought), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.38% below its high and over 100.0% above its low. Average 10-day trading volume of 1.03 million shares is slightly above the 3-month average of 832.67 thousand, indicating heightened recent market interest.

Nkarta, Inc. generated EPS of -$1.39 over the past year. Five-year average earnings growth is -19.86%. Wall Street analysts project EPS growth of 6.37% annually over the next five years. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.31. Next year's EPS is expected at $3.33. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $10.00. The high target offers 330.11% upside. The low target suggests 258.42% downside. The mean target is $11.17. This offers 300.36% upside. Nkarta, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -5.13%. The prior quarter beat by 15.62%. Over the last six quarters, Apple has recorded several small beats. These include -14.63% in March 26, 2025.

Nkarta, Inc. has 71.02 million shares outstanding. The public float is 52.51 million shares, elevated short interest at 15.09% of float. This equals 8.08 million shares. The short ratio is 14.5 days. Institutional investors hold 82.04% of the float. Insiders own 4.96%. GLAXOSMITHKLINE PLC holds 3.15 million shares, RA CAPITAL MANAGEMENT, L.P. has 3.00 million shares and Sonsini Peter W. has 2.90 million shares. Over the past six months, insider transactions show net selling. They sold 33.47 thousand shares across 3 transactions.

Nkarta, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.50. This means the shares are trading below this model’s fair value.

Nkarta, Inc. (NASDAQ:NKTX) closed at $2.79 USD, losing -$0.18 (-6.06%) from the previous close of $2.97. The stock is currently mid-range between its 52-week high and low $1.70 and $3.72. With a market capitalization of about $199.61 million, Nkarta, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.92). Key stats such as the average daily volume over the past year has been around 838.46 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Nkarta, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul J. Hastings, the company employs approximately 108 people and listed since July 10, 2020. Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Nkarta, Inc. trades at a P/E ratio of -2.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.72 suggesting the stock is closer to book value. The P/FCF stands at -2.24, also above market averages.

Nkarta, Inc. (NASDAQ:NKTX) shares are up 10.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nkarta, Inc. trading at a premium to the broader market with a P/E of -2.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.14, suggesting 621.86% upside. Our AI forecast model points to short-term strength (9.68% over two weeks), a medium-term rise (93.55% over three months), and a longer-term gain (460.22% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Nkarta, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.68%, with price expected at $3.06 by July 27, 2026, within a range of $2.79 to $3.37 3-Month Outlook: Projected rise of 93.55%, reaching $5.40 by October 08, 2026, with a range of $5.30 to $5.53. 1-Year Outlook: Projected gain of 460.22%, with price at $15.63 by July 13, 2027, within a range of $3.25 to $25.56.